EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Effect of CYP 3A4*1B and CYP3A5*3 Gene Polymorphisms in Antirejection of Tacrolimus in Liver Transplant Patients

Xia Zhou, Rujia Tang, Dali Zhang, Xi He, Zhenwen Liu, Yinjie Gao, Hongling Liu

Transplantation Proceedings · 2025

DOI: 10.1016/j.transproceed.2024.10.030 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Transplantation Proceedings, 2025. Verfasst von Xia Zhou und 6 weiteren Autor:innen. Beteiligte Einrichtung: From the Senior Department of Hepatology, the Fifth Medical Center, Chinese PLA General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Tacrolimus, Cytochrome P-450 CYP3A, Liver Transplantation, Immunosuppressive Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Tacrolimus is a substrate of CYP 3A5; to reduce the rate of liver injury and rejection in liver transplant (LT) recipients, it is feasible to optimize the administration of tacrolimus by adding CYP gene polymorphism. METHODS: We divided 151 LT recipients randomly into an optimization group and a control group. All were tested routinely for clinical indicators such as FK506 trough concentration and biochemistry, and their complications and survival were observed. The optimization group additionally detected single nucleotide polymorphisms in the CYP 3A4*1B and CYP 3A5*3 genes. RESULTS: There were no significant differences in tacrolimus dosage, FK506 trough concentrations, and concentration/dose value between the 2 groups. In the optimization group, all patients tested CYP 3A4*1B as wild type. CYP 3A5*3 detection classification included 35 with the G/G mutation (45.5%) and 36 A/G wild-type individuals (46.8%). The concentration/dose values of G/G mutant patients were significantly higher than those of A/G wild-type and A/A mutant patients (G/G vs. A/G; P < .05), and no significant difference in FK506. CONCLUSION: The CYP 3A4*1B genotype has less influence on tacrolimus metabolism. The genetic polymorphism of CYP 3A5*3 is obvious and largely affects tacrolimus metabolism, and the variant patients need lower doses of tacrolimus to reach the target concentration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TacrolimusCytochrome P-450 CYP3ALiver TransplantationImmunosuppressive AgentsPolymorphism, Single NucleotideGraft RejectionHumansMaleFemaleMiddle AgedAdult

Substanzen

TacrolimusCytochrome P-450 CYP3AImmunosuppressive AgentsCYP3A5 protein, humanCYP3A4 protein, human

Autor:innen und Institutionen

  • From the Senior Department of Hepatology, the Fifth Medical Center, Chinese PLA General Hospital, Beijing, China.
  • From the Senior Department of Hepatology, the Fifth Medical Center, Chinese PLA General Hospital, Beijing, China. Electronic address: lhl7125@sina.com.

Zitieren

APA

Zhou, X., Tang, R., Zhang, D., He, X., Liu, Z., Gao, Y., & Liu, H. (2025). Effect of CYP 3A4*1B and CYP3A5*3 Gene Polymorphisms in Antirejection of Tacrolimus in Liver Transplant Patients. Transplantation Proceedings. https://doi.org/10.1016/j.transproceed.2024.10.030

Vancouver

Zhou X, Tang R, Zhang D, He X, Liu Z, Gao Y, et al. Effect of CYP 3A4*1B and CYP3A5*3 Gene Polymorphisms in Antirejection of Tacrolimus in Liver Transplant Patients. Transplantation Proceedings. 2025. doi:10.1016/j.transproceed.2024.10.030

BibTeX
@article{Zhou2025,
  author = {Zhou, Xia and Tang, Rujia and Zhang, Dali and He, Xi and Liu, Zhenwen and Gao, Yinjie and Liu, Hongling},
  title = {Effect of CYP 3A4*1B and CYP3A5*3 Gene Polymorphisms in Antirejection of Tacrolimus in Liver Transplant Patients},
  journal = {Transplantation Proceedings},
  year = {2025},
  doi = {10.1016/j.transproceed.2024.10.030}
}
Kostenlos starten →